View Past PerformanceMirion Technologies バランスシートの健全性財務の健全性 基準チェック /36Mirion Technologiesの総株主資本は$1.5B 、総負債は$832.8Mで、負債比率は55%となります。総資産と総負債はそれぞれ$2.7Bと$1.2Bです。 Mirion Technologiesの EBIT は$48.5Mで、利息カバレッジ比率1.1です。現金および短期投資は$268.7Mです。主要情報55.02%負債資本比率US$832.80m負債インタレスト・カバレッジ・レシオ1.1x現金US$268.70mエクイティUS$1.51b負債合計US$1.22b総資産US$2.74b財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Fiscal Year Ending December 31, 2026Mirion Technologies, Inc. reaffirmed earnings guidance for the fiscal year ending December 31, 2026. For the year, the company expects Revenue growth of approximately 22.0% – 24.0%; includes foreign exchange rate and acquisition-related tailwinds.お知らせ • Apr 16Mirion Technologies, Inc. to Report Q1, 2026 Results on Apr 28, 2026Mirion Technologies, Inc. announced that they will report Q1, 2026 results After-Market on Apr 28, 2026お知らせ • Apr 02Mirion Technologies, Inc., Annual General Meeting, May 13, 2026Mirion Technologies, Inc., Annual General Meeting, May 13, 2026.お知らせ • Feb 11+ 1 more updateMirion Technologies, Inc. Announces Management AppointmentsMirion Technologies, Inc. announced three new leadership appointments supporting the company’s continued focus on safety, innovation, operational excellence and long-term growth. Mirion has promoted Tighe Smith to the newly created role of Chief Nuclear Officer. Reporting to Thomas Logan, Mirion Chairman and Chief Executive Officer, Smith will lead the company’s global nuclear strategy across the existing operating fleet as well as the rapidly expanding advanced and small modular reactor (SMR) markets. Smith brings more than 20 years of experience spanning nuclear engineering, digital safety systems, international commercial leadership, and industry policy engagement. Smith most recently held the Chief Nuclear Officer role at Paragon Energy Solutions, now part of Mirion, and will retain these duties in addition to his expanded role. He is also an active contributor to the broader nuclear community, serving as a Trustee of the American Nuclear Society and as Convenor of IEC SC45A Working Group 9, helping advance international standards for nuclear instrumentation and control. He holds a Bachelor of Science in Nuclear Engineering and an MBA from the University of Tennessee, Knoxville. In addition to Nuclear Power, Nuclear Medicine serves as a robust, continually evolving market for Mirion. To further support Mirion’s strategic growth in this key market, Shelia Webb becomes President of Nuclear Medicine. In this role, Webb will lead the overall Nuclear Medicine business unit, focusing on strategic development and furthering the integration of the ec Software and Capintec brands to support advanced cancer care. Webb most recently served as Mirion Chief Digital Officer, playing a pivotal role in building a digital ecosystem that connects operating groups and enhances Mirion capabilities, efficiency and value. Following Mirion’s acquisition of ecSoftware in 2023, Webb assumed responsibility of business unit leader for ec Software and has been instrumental in integrating the company into the broader Capintec portfolio. Mirion also announced the appointment of Shahmeer Mirza as the company’s inaugural Chief Artificial Intelligence & Digital Officer, a new role intended to accelerate Mirion’s commitment to operational excellence and scalable growth through responsible, transformative AI strategies. In this role, Mirza assumes responsibility for Mirion’s Digital strategy as Webb transitions to the role of President, Nuclear Medicine. As Chief AI and Digital Officer, Mirza will lead the continuation of Mirion’s digital transformation roadmap leveraging technologies like AI to innovate, improve processes, and create new revenue streams. Reporting directly to Logan, Mirza will shape and execute the company’s AI vision, helping establish AI as a core enabler across the global business primarily through internal and enterprise applications. In this role, Mirza will lead the integration of advanced analytics, machine learning and intelligent automation across Mirion operations and processes. This will include identifying and prioritizing high-impact use cases; optimizing manufacturing and supply chain performance; and implementing governance frameworks for ethical, secure, transparent, and compliant AI use – particularly important in highly regulated environments. Mirza previously served as Senior Director of Data, AI/Machine Learning, and Research and Development at 7-Eleven, where he led enterprise data and AI strategies in support of multi-million-dollar incremental sales. He holds over 130 patents, earned a Master of Science in Computer Science and a Bachelor of Science in Chemical and Biomolecular Engineering from the Georgia Institute of Technology.お知らせ • Jan 22Mirion Technologies, Inc. to Report Q4, 2025 Results on Feb 10, 2026Mirion Technologies, Inc. announced that they will report Q4, 2025 results After-Market on Feb 10, 2026お知らせ • Dec 02Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC.Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million on September 24, 2025. The transaction is subject to working capital and other customary purchase price adjustments. The financing of the Acquisition, Mirion has obtained $585 million in incremental term loan commitments from Goldman Sachs Lending Partners LLC, pursuant to a debt commitment letter and is supported by a fully committed bridge facility. The transaction will also be financed through a $350 million public offering and $250 Million convertible notes due 2031.The transaction is valued at an approximate multiple of 18 times the estimated 2026 Adjusted EBITDA. The closing of the Acquisition is subject to customary closing conditions, including: (i) expiration or termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and receipt of approval from the U.S. Nuclear Regulatory Commission related to the transfer of a nuclear export license, (ii) the absence of any law, injunction or other governmental order that prohibits the consummation of the Acquisition; and (iii) other customary closing conditions, including the accuracy of the parties’ representations and warranties (subject to certain materiality qualifications) and each party’s compliance with its covenants and agreements contained in the Equity Purchase Agreement. The transaction is expected to close before year end 2025. The acquisition is anticipated to be accretive to diluted EPS in the first full year post close. Goldman Sachs & Co. LLC acted as financial advisor for Mirion Technologies, Inc. Alan F. Denenberg, Michael Diz, Hilary Dengel, Frank Azzopardi, Patrick E. Sigmon and Adam Kaminsky of Davis Polk & Wardwell LLP acted as legal advisor for Mirion Technologies, Inc. Robert W. Baird & Co. Incorporated acted as financial advisor for Paragon Energy Solutions, LLC. Moelis & Company acted as financial advisor for Paragon Energy Solutions, LLC. Annie Cataldo, Amanda C. Border, Christian A. Atwood and Vincent P. Thorn of Kirkland & Ellis LLP acted as legal advisor for Paragon Energy Solutions, LLC. Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC on December 1, 2025.お知らせ • Oct 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Full Year Ending December 31, 2025Mirion Technologies, Inc. reaffirmed earnings guidance for the full year ending December 31, 2025. For the year, the company reaffirmed revenue growth of approximately 7.0% – 9.0%; includes a foreign exchange rate tailwind of approximately 180 basis points using a fourth quarter Euro-to-USD exchange rate of 1.16 and acquisitions-related benefit (Certrec and Oncospace) of approximately 100 basis points. Organic Revenue growth of approximately 4.5% – 6.0%.お知らせ • Oct 16Mirion Technologies, Inc. to Report Q3, 2025 Results on Oct 28, 2025Mirion Technologies, Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Oct 28, 2025お知らせ • Sep 26Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $369.565212 million.Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $369.565212 million. Security Name: Class A Common Stock Security Type: Common Stock Securities Offered: 17,309,846 Price\Range: $21.35お知らせ • Sep 25Mirion Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $349.999993 million.Mirion Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $349.999993 million. Security Name: Class A Common Stock Security Type: Common Stock Securities Offered: 14,227,642 Price\Range: $24.6お知らせ • Sep 24Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million.Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million on September 24, 2025. The transaction is subject to working capital and other customary purchase price adjustments. The financing of the Acquisition, Mirion has obtained $585 million in incremental term loan commitments from Goldman Sachs Lending Partners LLC, pursuant to a debt commitment letter and is supported by a fully committed bridge facility. The closing of the Acquisition is subject to customary closing conditions, including: (i) expiration or termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and receipt of approval from the U.S. Nuclear Regulatory Commission related to the transfer of a nuclear export license, (ii) the absence of any law, injunction or other governmental order that prohibits the consummation of the Acquisition; and (iii) other customary closing conditions, including the accuracy of the parties’ representations and warranties (subject to certain materiality qualifications) and each party’s compliance with its covenants and agreements contained in the Equity Purchase Agreement. The transaction is expected to close before year end 2025. The acquisition is anticipated to be accretive to diluted EPS in the first full year post close. Goldman Sachs & Co. LLC acted as financial advisor for Mirion Technologies, Inc. Alan F. Denenberg, Michael Diz, Hilary Dengel, Frank Azzopardi, Patrick E. Sigmon and Adam Kaminsky of Davis Polk & Wardwell LLP acted as legal advisor for Mirion Technologies, Inc. Robert W. Baird & Co. Incorporated acted as financial advisor for Paragon Energy Solutions, LLC. Moelis & Company acted as financial advisor for Paragon Energy Solutions, LLC. Annie Cataldo, Amanda C. Border, Christian A. Atwood and Vincent P. Thorn of Kirkland & Ellis LLP acted as legal advisor for Paragon Energy Solutions, LLC.お知らせ • Aug 01+ 1 more updateMirion Technologies, Inc. Updates Earnings Guidance for the Fiscal Year Ending December 31, 2025Mirion Technologies, Inc. updated earnings guidance for the fiscal year ending December 31, 2025. For the year, the company expected revenue growth of approximately 7.0% to 9.0% (previously 5.0% to 7.0%); includes a foreign exchange rate tailwind of approximately 125 basis points using a Euro-to-USD exchange rate of 1.15 and acquisitions-related tailwind of approximately 100 basis points. Organic Revenue growth of approximately 5.0% to 7.0% (previously 5.5% to 7.5%); includes increased Nuclear Power end-market expected growth which is more than offset by reductions to Labs & Research and Dosimetry end-markets expectations.お知らせ • Jul 22Mirion Technologies Unveils the Vital Platform, a Digital Ecosystem Powering Integrated Operations for Nuclear Energy and BeyondMirion Technologies announced the launch of the Vital Platform. This software offers a single, unified system for accessing data across nuclear power sites to work more efficiently, enhance worker safety, and solve operational challenges faster. The launch includes the platform's first application, Vital Supervision, designed to enhance radiological instrument data visibility, improve response times, and simplify oversight across critical radiological systems. The Vital Platform was developed to meet nuclear industry demands for a more connected and efficient way to manage radiological instrument data. Rather than relying on fragmented systems or manual processes, Vital enables teams to work within one streamlined environment prioritizing speed, security, and long-term adaptability. Key benefits to customers include: Data Integration and Real Time Monitoring: Real-time tracking across systems enables faster, proactive responses. Regulatory Compliance and Reporting: Automated, standardized reporting simplifies regulatory alignment. Operational Efficiency and Cost Reduction: Streamlined workflows cut time, reduce errors, and lower costs. Security and Risk Mitigation: Access controls and cybersecurity safeguard sensitive data. Facilitating Advanced Analytics: Detailed data helps predict risks and improve decision-making. Scalability and Future Proofing: Modular design supports growth and adapts to change. Supervision: The First Vital Platform Application. Vital Supervision is the first in a series of applications to be built on the Vital Platform, with the aim to unify the capabilities of siloed, standalone software into one platform. This application simplifies the collection and analysis of data from a wide variety of radiological instruments. Real-time, at-a-glance access to alarms, measurement data and instrument health significantly enhances the monitoring and management of critical equipment. The Vital Platform and Vital Supervision application will be showcased at two key upcoming industry events. A webbinar presentation facilitated through Nuclear Engineering International (July 23) and Mirion's annual users' conference Mirion Connect (July 28-August 1) will offer opportunities to explore platform capabilities in depth.お知らせ • Jul 17Mirion Technologies, Inc. to Report Q2, 2025 Results on Jul 31, 2025Mirion Technologies, Inc. announced that they will report Q2, 2025 results After-Market on Jul 31, 2025お知らせ • Jun 30+ 4 more updatesMirion Technologies, Inc.(NYSE:MIR) dropped from Russell 3000E Value IndexMirion Technologies, Inc.(NYSE:MIR) dropped from Russell 3000E Value IndexBoard Change • Jun 20Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Independent Director Sheila Rege was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jun 20Mirion Medical to Debut New Solutions, Highlight Broad Radiopharma-Focused Portfolio At Snmmi Annual MeetingMirion announced that its Mirion Medical group will showcase its portfolio of solutions designed to enable the radiopharma and theranostic fields at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 21-24, in New Orleans, Louisiana. New products from Capintec and Dosimetry Services will be introduced alongside innovations from the broader Mirion portfolio, including the ec2 Software suite and advances from Mirion Technologies. Deuting at the 2025 SNMMI Annual Meeting: Graves Phantom from Capintec, a Mirion Medical company: The Graves Phantom is a solution for enabling precise dosimetry in radiopharmaceutical therapy (RPT). Designed as a 20-cm tissue-equivalent Phantom, it supports the calibration of SPECT systems per radioisotope and allows for accurate sensitivity factor measurements under realistic scatter conditions, enabling reliable and reproducible RPT workflows. Instadose®?VUE Beta Dosimeter from Dosimetry Services, a Mirion Medical company; The only hybrid wireless dosimeter designed for theranostic applications, the InstadoseVUE Beta device tracks and measures radiation exposure, ensuring the safety of medical staff in environments where beta radiation is present. The InstadoseVUE Beta is the latest model in the InstadoseVUE line of wireless dosimeters for radiation monitoring of personnel. Additional Featured Solutions from the Broader Mirion Portfolio: ec2 Software Suite: ec2 Software, a Mirion Medical company, provides software to simplify workflows, support regulatory compliance, and drive operational efficiency for stakeholders across the nuclear medicine, molecular imaging and radiopharmaceutical fields. Demonstrations for applications including BioTrax™? QMS, NMIS™?, and BioRx™? will be available throughout the SNMMI Annual Meeting. Apex-Guard™? Software: From Mirion Technologies, the newest version of Apex-Guard software includes a robust impurity analysis feature and patent-pending algorithm for gamma spectroscopy measurements, which simplifies radioisotope production quality management, boosts confidence in radioisotope safety, and aids in regulatory compliance. The software integrates with BioTrax QMS, improving workflow efficiency and data integrity. Portable and Mobile Radiation Monitoring: New solutions from Mirion Technologies include the CSPevo®? Probe and RDS-Med™? Survey Meter for comprehensive, portable radiation survey monitoring and the IC3™? Portable Ion Chamber Survey Meter for measuring gamma, beta and X-ray radiation. In addition, the iCAM™? Mobile Alpha/Beta Particulate Monitor for reliable monitoring of airborne activity will be on hand. Commitment to Patient Care and Safety: Mirion Medical is a proud sponsor of the SNMMI 2025 Patient Education Day, contributing educational resources and insights on radiation safety. This sponsorship reflects Mirion's commitment to patient education and awareness, ensuring that patients and their families are well-informed about the benefits of nuclear medicine and molecular imaging.財務状況分析短期負債: MIR *の 短期資産 ( $693.2M ) が 短期負債 ( $272.4M ) を超えています。長期負債: MIR *の短期資産 ( $693.2M ) は 長期負債 ( $951.8M ) をカバーしていません。デット・ツー・エクイティの歴史と分析負債レベル: MIR *の 純負債対資本比率 ( 37.3% ) は 満足できる 水準であると考えられます。負債の削減: MIR *は 5 年前には株主資本がマイナスでしたが、現在はプラスになっており、改善されています。債務返済能力: MIR *の負債は 営業キャッシュフロー によって 十分にカバーされていません ( 15.1% )。インタレストカバレッジ: MIR *の負債に対する 利息支払い は EBIT ( 1.1 x coverage) によって 十分にカバーされていません。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YTech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/09/17 12:48終値2025/06/20 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Mirion Technologies, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12 アナリスト機関Quinn FredricksonBairdRobert MasonBairdYuan ZhiB. Riley Securities, Inc.9 その他のアナリストを表示
お知らせ • Apr 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Fiscal Year Ending December 31, 2026Mirion Technologies, Inc. reaffirmed earnings guidance for the fiscal year ending December 31, 2026. For the year, the company expects Revenue growth of approximately 22.0% – 24.0%; includes foreign exchange rate and acquisition-related tailwinds.
お知らせ • Apr 16Mirion Technologies, Inc. to Report Q1, 2026 Results on Apr 28, 2026Mirion Technologies, Inc. announced that they will report Q1, 2026 results After-Market on Apr 28, 2026
お知らせ • Apr 02Mirion Technologies, Inc., Annual General Meeting, May 13, 2026Mirion Technologies, Inc., Annual General Meeting, May 13, 2026.
お知らせ • Feb 11+ 1 more updateMirion Technologies, Inc. Announces Management AppointmentsMirion Technologies, Inc. announced three new leadership appointments supporting the company’s continued focus on safety, innovation, operational excellence and long-term growth. Mirion has promoted Tighe Smith to the newly created role of Chief Nuclear Officer. Reporting to Thomas Logan, Mirion Chairman and Chief Executive Officer, Smith will lead the company’s global nuclear strategy across the existing operating fleet as well as the rapidly expanding advanced and small modular reactor (SMR) markets. Smith brings more than 20 years of experience spanning nuclear engineering, digital safety systems, international commercial leadership, and industry policy engagement. Smith most recently held the Chief Nuclear Officer role at Paragon Energy Solutions, now part of Mirion, and will retain these duties in addition to his expanded role. He is also an active contributor to the broader nuclear community, serving as a Trustee of the American Nuclear Society and as Convenor of IEC SC45A Working Group 9, helping advance international standards for nuclear instrumentation and control. He holds a Bachelor of Science in Nuclear Engineering and an MBA from the University of Tennessee, Knoxville. In addition to Nuclear Power, Nuclear Medicine serves as a robust, continually evolving market for Mirion. To further support Mirion’s strategic growth in this key market, Shelia Webb becomes President of Nuclear Medicine. In this role, Webb will lead the overall Nuclear Medicine business unit, focusing on strategic development and furthering the integration of the ec Software and Capintec brands to support advanced cancer care. Webb most recently served as Mirion Chief Digital Officer, playing a pivotal role in building a digital ecosystem that connects operating groups and enhances Mirion capabilities, efficiency and value. Following Mirion’s acquisition of ecSoftware in 2023, Webb assumed responsibility of business unit leader for ec Software and has been instrumental in integrating the company into the broader Capintec portfolio. Mirion also announced the appointment of Shahmeer Mirza as the company’s inaugural Chief Artificial Intelligence & Digital Officer, a new role intended to accelerate Mirion’s commitment to operational excellence and scalable growth through responsible, transformative AI strategies. In this role, Mirza assumes responsibility for Mirion’s Digital strategy as Webb transitions to the role of President, Nuclear Medicine. As Chief AI and Digital Officer, Mirza will lead the continuation of Mirion’s digital transformation roadmap leveraging technologies like AI to innovate, improve processes, and create new revenue streams. Reporting directly to Logan, Mirza will shape and execute the company’s AI vision, helping establish AI as a core enabler across the global business primarily through internal and enterprise applications. In this role, Mirza will lead the integration of advanced analytics, machine learning and intelligent automation across Mirion operations and processes. This will include identifying and prioritizing high-impact use cases; optimizing manufacturing and supply chain performance; and implementing governance frameworks for ethical, secure, transparent, and compliant AI use – particularly important in highly regulated environments. Mirza previously served as Senior Director of Data, AI/Machine Learning, and Research and Development at 7-Eleven, where he led enterprise data and AI strategies in support of multi-million-dollar incremental sales. He holds over 130 patents, earned a Master of Science in Computer Science and a Bachelor of Science in Chemical and Biomolecular Engineering from the Georgia Institute of Technology.
お知らせ • Jan 22Mirion Technologies, Inc. to Report Q4, 2025 Results on Feb 10, 2026Mirion Technologies, Inc. announced that they will report Q4, 2025 results After-Market on Feb 10, 2026
お知らせ • Dec 02Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC.Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million on September 24, 2025. The transaction is subject to working capital and other customary purchase price adjustments. The financing of the Acquisition, Mirion has obtained $585 million in incremental term loan commitments from Goldman Sachs Lending Partners LLC, pursuant to a debt commitment letter and is supported by a fully committed bridge facility. The transaction will also be financed through a $350 million public offering and $250 Million convertible notes due 2031.The transaction is valued at an approximate multiple of 18 times the estimated 2026 Adjusted EBITDA. The closing of the Acquisition is subject to customary closing conditions, including: (i) expiration or termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and receipt of approval from the U.S. Nuclear Regulatory Commission related to the transfer of a nuclear export license, (ii) the absence of any law, injunction or other governmental order that prohibits the consummation of the Acquisition; and (iii) other customary closing conditions, including the accuracy of the parties’ representations and warranties (subject to certain materiality qualifications) and each party’s compliance with its covenants and agreements contained in the Equity Purchase Agreement. The transaction is expected to close before year end 2025. The acquisition is anticipated to be accretive to diluted EPS in the first full year post close. Goldman Sachs & Co. LLC acted as financial advisor for Mirion Technologies, Inc. Alan F. Denenberg, Michael Diz, Hilary Dengel, Frank Azzopardi, Patrick E. Sigmon and Adam Kaminsky of Davis Polk & Wardwell LLP acted as legal advisor for Mirion Technologies, Inc. Robert W. Baird & Co. Incorporated acted as financial advisor for Paragon Energy Solutions, LLC. Moelis & Company acted as financial advisor for Paragon Energy Solutions, LLC. Annie Cataldo, Amanda C. Border, Christian A. Atwood and Vincent P. Thorn of Kirkland & Ellis LLP acted as legal advisor for Paragon Energy Solutions, LLC. Mirion Technologies, Inc. (NYSE:MIR) completed the acquisition of Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC on December 1, 2025.
お知らせ • Oct 29Mirion Technologies, Inc. Reaffirms Earnings Guidance for the Full Year Ending December 31, 2025Mirion Technologies, Inc. reaffirmed earnings guidance for the full year ending December 31, 2025. For the year, the company reaffirmed revenue growth of approximately 7.0% – 9.0%; includes a foreign exchange rate tailwind of approximately 180 basis points using a fourth quarter Euro-to-USD exchange rate of 1.16 and acquisitions-related benefit (Certrec and Oncospace) of approximately 100 basis points. Organic Revenue growth of approximately 4.5% – 6.0%.
お知らせ • Oct 16Mirion Technologies, Inc. to Report Q3, 2025 Results on Oct 28, 2025Mirion Technologies, Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Oct 28, 2025
お知らせ • Sep 26Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $369.565212 million.Mirion Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $369.565212 million. Security Name: Class A Common Stock Security Type: Common Stock Securities Offered: 17,309,846 Price\Range: $21.35
お知らせ • Sep 25Mirion Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $349.999993 million.Mirion Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $349.999993 million. Security Name: Class A Common Stock Security Type: Common Stock Securities Offered: 14,227,642 Price\Range: $24.6
お知らせ • Sep 24Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million.Mirion Technologies, Inc. (NYSE:MIR) entered into a definitive agreement to acquire Paragon Energy Solutions, LLC from Windjammer Capital Investors LLC for approximately $590 million on September 24, 2025. The transaction is subject to working capital and other customary purchase price adjustments. The financing of the Acquisition, Mirion has obtained $585 million in incremental term loan commitments from Goldman Sachs Lending Partners LLC, pursuant to a debt commitment letter and is supported by a fully committed bridge facility. The closing of the Acquisition is subject to customary closing conditions, including: (i) expiration or termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, and receipt of approval from the U.S. Nuclear Regulatory Commission related to the transfer of a nuclear export license, (ii) the absence of any law, injunction or other governmental order that prohibits the consummation of the Acquisition; and (iii) other customary closing conditions, including the accuracy of the parties’ representations and warranties (subject to certain materiality qualifications) and each party’s compliance with its covenants and agreements contained in the Equity Purchase Agreement. The transaction is expected to close before year end 2025. The acquisition is anticipated to be accretive to diluted EPS in the first full year post close. Goldman Sachs & Co. LLC acted as financial advisor for Mirion Technologies, Inc. Alan F. Denenberg, Michael Diz, Hilary Dengel, Frank Azzopardi, Patrick E. Sigmon and Adam Kaminsky of Davis Polk & Wardwell LLP acted as legal advisor for Mirion Technologies, Inc. Robert W. Baird & Co. Incorporated acted as financial advisor for Paragon Energy Solutions, LLC. Moelis & Company acted as financial advisor for Paragon Energy Solutions, LLC. Annie Cataldo, Amanda C. Border, Christian A. Atwood and Vincent P. Thorn of Kirkland & Ellis LLP acted as legal advisor for Paragon Energy Solutions, LLC.
お知らせ • Aug 01+ 1 more updateMirion Technologies, Inc. Updates Earnings Guidance for the Fiscal Year Ending December 31, 2025Mirion Technologies, Inc. updated earnings guidance for the fiscal year ending December 31, 2025. For the year, the company expected revenue growth of approximately 7.0% to 9.0% (previously 5.0% to 7.0%); includes a foreign exchange rate tailwind of approximately 125 basis points using a Euro-to-USD exchange rate of 1.15 and acquisitions-related tailwind of approximately 100 basis points. Organic Revenue growth of approximately 5.0% to 7.0% (previously 5.5% to 7.5%); includes increased Nuclear Power end-market expected growth which is more than offset by reductions to Labs & Research and Dosimetry end-markets expectations.
お知らせ • Jul 22Mirion Technologies Unveils the Vital Platform, a Digital Ecosystem Powering Integrated Operations for Nuclear Energy and BeyondMirion Technologies announced the launch of the Vital Platform. This software offers a single, unified system for accessing data across nuclear power sites to work more efficiently, enhance worker safety, and solve operational challenges faster. The launch includes the platform's first application, Vital Supervision, designed to enhance radiological instrument data visibility, improve response times, and simplify oversight across critical radiological systems. The Vital Platform was developed to meet nuclear industry demands for a more connected and efficient way to manage radiological instrument data. Rather than relying on fragmented systems or manual processes, Vital enables teams to work within one streamlined environment prioritizing speed, security, and long-term adaptability. Key benefits to customers include: Data Integration and Real Time Monitoring: Real-time tracking across systems enables faster, proactive responses. Regulatory Compliance and Reporting: Automated, standardized reporting simplifies regulatory alignment. Operational Efficiency and Cost Reduction: Streamlined workflows cut time, reduce errors, and lower costs. Security and Risk Mitigation: Access controls and cybersecurity safeguard sensitive data. Facilitating Advanced Analytics: Detailed data helps predict risks and improve decision-making. Scalability and Future Proofing: Modular design supports growth and adapts to change. Supervision: The First Vital Platform Application. Vital Supervision is the first in a series of applications to be built on the Vital Platform, with the aim to unify the capabilities of siloed, standalone software into one platform. This application simplifies the collection and analysis of data from a wide variety of radiological instruments. Real-time, at-a-glance access to alarms, measurement data and instrument health significantly enhances the monitoring and management of critical equipment. The Vital Platform and Vital Supervision application will be showcased at two key upcoming industry events. A webbinar presentation facilitated through Nuclear Engineering International (July 23) and Mirion's annual users' conference Mirion Connect (July 28-August 1) will offer opportunities to explore platform capabilities in depth.
お知らせ • Jul 17Mirion Technologies, Inc. to Report Q2, 2025 Results on Jul 31, 2025Mirion Technologies, Inc. announced that they will report Q2, 2025 results After-Market on Jul 31, 2025
お知らせ • Jun 30+ 4 more updatesMirion Technologies, Inc.(NYSE:MIR) dropped from Russell 3000E Value IndexMirion Technologies, Inc.(NYSE:MIR) dropped from Russell 3000E Value Index
Board Change • Jun 20Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Independent Director Sheila Rege was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 20Mirion Medical to Debut New Solutions, Highlight Broad Radiopharma-Focused Portfolio At Snmmi Annual MeetingMirion announced that its Mirion Medical group will showcase its portfolio of solutions designed to enable the radiopharma and theranostic fields at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 21-24, in New Orleans, Louisiana. New products from Capintec and Dosimetry Services will be introduced alongside innovations from the broader Mirion portfolio, including the ec2 Software suite and advances from Mirion Technologies. Deuting at the 2025 SNMMI Annual Meeting: Graves Phantom from Capintec, a Mirion Medical company: The Graves Phantom is a solution for enabling precise dosimetry in radiopharmaceutical therapy (RPT). Designed as a 20-cm tissue-equivalent Phantom, it supports the calibration of SPECT systems per radioisotope and allows for accurate sensitivity factor measurements under realistic scatter conditions, enabling reliable and reproducible RPT workflows. Instadose®?VUE Beta Dosimeter from Dosimetry Services, a Mirion Medical company; The only hybrid wireless dosimeter designed for theranostic applications, the InstadoseVUE Beta device tracks and measures radiation exposure, ensuring the safety of medical staff in environments where beta radiation is present. The InstadoseVUE Beta is the latest model in the InstadoseVUE line of wireless dosimeters for radiation monitoring of personnel. Additional Featured Solutions from the Broader Mirion Portfolio: ec2 Software Suite: ec2 Software, a Mirion Medical company, provides software to simplify workflows, support regulatory compliance, and drive operational efficiency for stakeholders across the nuclear medicine, molecular imaging and radiopharmaceutical fields. Demonstrations for applications including BioTrax™? QMS, NMIS™?, and BioRx™? will be available throughout the SNMMI Annual Meeting. Apex-Guard™? Software: From Mirion Technologies, the newest version of Apex-Guard software includes a robust impurity analysis feature and patent-pending algorithm for gamma spectroscopy measurements, which simplifies radioisotope production quality management, boosts confidence in radioisotope safety, and aids in regulatory compliance. The software integrates with BioTrax QMS, improving workflow efficiency and data integrity. Portable and Mobile Radiation Monitoring: New solutions from Mirion Technologies include the CSPevo®? Probe and RDS-Med™? Survey Meter for comprehensive, portable radiation survey monitoring and the IC3™? Portable Ion Chamber Survey Meter for measuring gamma, beta and X-ray radiation. In addition, the iCAM™? Mobile Alpha/Beta Particulate Monitor for reliable monitoring of airborne activity will be on hand. Commitment to Patient Care and Safety: Mirion Medical is a proud sponsor of the SNMMI 2025 Patient Education Day, contributing educational resources and insights on radiation safety. This sponsorship reflects Mirion's commitment to patient education and awareness, ensuring that patients and their families are well-informed about the benefits of nuclear medicine and molecular imaging.